OPPOSITE: Outcome Prediction of Systemic Treatment in Esophagogastric Carcinoma

NACompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

April 15, 2018

Primary Completion Date

November 1, 2021

Study Completion Date

November 30, 2023

Conditions
Gastric NeoplasmGastroesophageal Junction AdenocarcinomaEsophageal AdenocarcinomaGastric AdenocarcinomaEsophageal Neoplasms
Interventions
PROCEDURE

Biopsy

Patients with locally advanced, resectable gastric or esophagogastric junction adenocarcinoma will receive a biopsy of the primary tumor, followed by standard-of care neoadjuvant systemic treatment; after neoadjuvant therapy tumor biopsies will be taken from different sites of the resection specimen.

Trial Locations (2)

Unknown

University Hospital Dresden, Dresden

National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg

All Listed Sponsors
collaborator

University Hospital Dresden

OTHER

collaborator

German Cancer Research Center

OTHER

lead

University Hospital Heidelberg

OTHER

NCT03429816 - OPPOSITE: Outcome Prediction of Systemic Treatment in Esophagogastric Carcinoma | Biotech Hunter | Biotech Hunter